Orphan Drug Designation: a pathway to accessible treatment for rare diseases
The term ‘Orphan Drugs’ refers to medicines developed to treat medical conditions, considered to be rare. In Australia, if a medicine is intended to treat a condition
Accelagen facilitates LEDAGA Approval in Australia
LEDAGA® (Chlormethine hydrochloride) – TGA APPROVAL Accelagen, a Melbourne based Regulatory Affairs, Clinical Research and Development Organisation, are pleased to